Recurrent Rectal Cancer Completed Phase 1 Trials for Sargramostim (DB00020)

Also known as: Rectal cancer recurrent / Carcinoma rectum recurrent / Rectal carcinoma recurrent / Carcinoma of rectum recurrent

IndicationStatusPhase
DBCOND0028583 (Recurrent Rectal Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00028496Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerTreatment